Dental Division
Supporting Dental Professionals with Advanced Compounded Solutions
Ventis Pharma is dedicated to providing healthcare professionals with high-quality compounded preparations produced under Section 503B of the Federal Food, Drug, and Cosmetic Act. Our Dental Division focuses on offering products that meet the clinical needs of oral and maxillofacial practitioners seeking consistent quality and dependable performance.
Compliance Statement
All Ventis Pharma compounded preparations are produced in FDA-registered 503B Outsourcing Facilities that comply with current Good Manufacturing Practices (cGMP). These products are made on a per-order basis for office use by licensed healthcare professionals. They are not intended for individual patient dispensing or direct-to-consumer promotion.
For professional inquiries or order requests:
Ventis Pharma Dental Division
www.ventispharmadental.com
Dental Portfolio
Endura-KT™ (Lidocaine / Tetracaine / Epinephrine)
An FDA 503B compounded local anesthetic preparation for procedural use in oral and dental settings
Endura-KT™ is a sterile, preservative-free local anesthetic solution compounded under FDA 503B Outsourcing Facility standards. It contains lidocaine, tetracaine, and epinephrine in a formulation designed to support clinicians in managing procedural and post-operative discomfort.
Key Attributes (for Educational Use Only):
- Opioid-free formulation: Provides an alternative local anesthetic option without systemic opioid administration.
- Balanced concentrations: Formulated with dilute components to permit adequate volume administration at the procedural site.
- Sterile and preservative-free: Compounded in compliance with current Good Manufacturing Practice (cGMP).
- Broad dental applicability: Utilized by oral and dental professionals for procedures such as extractions, implant placement, periodontal and endodontic surgery, grafting, and related interventions.
- Extended local action: Reported by clinicians to provide sustained local effect appropriate for surgical and post-procedural settings.
Important Disclosure Notice:
Endura-KT™ is a compounded preparation and has not been reviewed or approved by the FDA for safety or efficacy. It is dispensed by prescription or order of a licensed practitioner for office or institutional use in accordance with federal and state law. The 503B Outsourcing Manufacturer facility is inspected and licensed by the FDA and the State Board of Pharmacy.
Sedare™ (Compounded Nasal Spray with Sufentanil and Ketamine)
A needle-free 503B preparation intended for supervised procedural use
Sedare™ Nasal Spray is compounded under FDA 503B Outsourcing Facility standards to provide clinicians with an option for needle-free administration of active pharmaceutical ingredients sufentanil and ketamine. The preparation is designed for use in controlled clinical environments where rapid onset and short procedural duration are desired.
Key Attributes (for Educational Use Only):
- Needle-free intranasal administration: May support patient comfort and workflow efficiency in appropriate supervised settings.
- Rapid onset and predictable duration: Pharmacologic characteristics of the active ingredients allow for onset within minutes and a short procedural window.
- Intended use setting: For administration by qualified healthcare professionals experienced with opioid and anesthetic agents.
- Potential applications: May be used under medical direction as an adjunct to local anesthesia or procedural sedation in dental or surgical environments.
Important Notice:
Sedare™ is a compounded drug product prepared in accordance with Section 503B of the FD&C Act and cGMP requirements. It has not been evaluated or approved by the FDA for any specific indication. Its use should be based on a clinician’s independent medical judgment and institutional protocols.